BioStone > Veterinary Biologics and Vaccine Solutions > Mannheimia haemolytica Bacterin-toxoid Vaccine Collaboration Opportunities
Mannheimia haemolytica Bacterin-toxoid Vaccine Collaboration Opportunities
BioStone Animal Health is seeking commercial partners and distributors interested in commercializing Mannheimia haemolytica vaccine solutions for cattle.
BioStone is currently evaluating two related collaboration pathways based on its M. haemolytica bacterin-toxoid platform:
MLV Combination Opportunity
Product Code G905.02
A further-manufacturing opportunity for companies with an existing modified-live-virus bovine respiratory disease vaccine platform.
G905.02 may be evaluated as a biologically active Mannheimia haemolytica component and reconstitution diluent for an MLV vaccine, subject to partner-specific compatibility, non-interference, and regulatory studies.
Explore the MLV Combination Opportunity
Standalone Vaccine Opportunity
Product Code 7905.02
A standalone Mannheimia haemolytica bacterin-toxoid development opportunity for companies interested in distribution and commercialization.
This opportunity may be suitable for partners seeking an MH-only respiratory vaccine for cattle or a differentiated product for U.S. or international markets.
Explore the Standalone Vaccine Opportunity
Why Collaborate With BioStone
BioStone offers:
- Experience developing and manufacturing veterinary bacterins and bacterin-toxoids
- Historical safety, potency, efficacy, and combination-product data
- An established USDA-licensed veterinary biologics manufacturing facility
- Technical expertise in bacterial antigen production and vaccine development
- Flexibility to support distribution partnerships
Who We Are Seeking
We welcome discussions with:
- Veterinary vaccine manufacturers
- Companies with MLV bovine respiratory vaccine platforms
- U.S. and international animal-health distributors
- Licensing and commercialization partners
- Organizations interested in supporting development or regulatory studies
Development Status
These programs are currently being presented as collaboration and development opportunities.
Future manufacture, distribution, combination use, and commercialization are subject to completion of applicable technical studies, reference qualification, partner-specific development work, and regulatory authorization.
Discuss a Collaboration
Companies interested in either development pathway are invited to contact BioStone Animal Health to discuss technical information, available data, potential study plans, and collaboration structures.